Journal articleClin Cancer Res2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
- Journal
- Clin Cancer Res
- Published
- 1 May 2026
- Citations
- 3
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsNiraparib in Patients With Pancreatic Cancer NCT03601923↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.
Grants 4
- Cost Effectiveness of Germline Genetic Testing in Pancreatic Cancer K08CA248473↗
- Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma P50CA127003↗
- Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer R01CA276268↗
- Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity U01CA274276↗